Efficacy and Toxicity of Postoperative Temozolomide Radiochemotherapy in Malignant Glioma

Abstract

Postoperative radiochemotherapy with 30-33 daily doses of temozolomide (75 mg/m(2)) is safe in patients with malignant glioma. The combined schedule is effective in oligodendroglioma patients and may prolong survival in glioblastoma. Effort should be taken to minimize corticosteroid doses, since both steroids and temozolomide lead to immunosuppression.

The Outcomes of Concomitant Chemoradiotherapy Followed by Adjuvant Chemotherapy with Temozolomide for Newly Diagnosed High Grade Gliomas : The Preliminary Results of Single Center Prospective Study

“…In 2005, the efficacy of postoperative TMZ radiochemotherapy in malignant glioma was reported in Germany 7) . According to that report, median PFS times were 7.3 and 8.7 months for primary glioblastoma and anaplastic astrocytoma, respectively, in patients treated with CCRT with TMZ.…”

Effect of Carbogen Breathing on the Radiation Response of a Human Glioblastoma Xenograft

“…The standard treatment of GBM consists of tumor debulking followed by radio-and chemotherapy [7,21,22,29,45]. The three resistance mechanisms that are most important for radiation treatment failure are intrinsic radiation resistance, tumor cell repopulation during treatment, and tumor hypoxia.…”

“…Images were recorded using a high-resolution intensified solid-state camera for quantitative analysis. A detailed description of this method was given before [22]. After scanning the whole tissue sections and reconstructing the fields into one composite image, the area of interest was reconstructed.…”

CT-Guided Interstitial HDR Brachytherapy for Recurrent Glioblastoma Multiforme

“…Despite this multimodal approach [16,27], the median survival remains disappointingly short, about 10 months in most reports, and less than 5% of patients survive more than 5 years after resection and RT [41], suggesting, among other things, that there is clinical heterogeneity in GBM radiosensitivity [6,10,22]. However, the efficacy of irradiation is not only limited by the inherent radioresistance of glioma cells, but also by the radiosensitivity of surrounding healthy brain tissue [6,10].…”